Vivoryon Therapeutics is a clinical stage biopharmaceutical company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins for patients living with severe diseases. The company focuses primarily on development of therapeutic products for the treatment of AD, cancer, inflammation, and fibrosis. Its lead product candidate, Varoglutamstat, is in Phase II clinical development for AD.
Vivoryon Therapeutics is listed on the regulated market of Euronext Amsterdam (Ticker: VVY) and headquartered in Halle, Germany.
In the last twelve months, Van Lanschot Kempen has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:
- Joint Global Coordinator & Joint Bookrunner in the €15.8 million Capital Increase by Sequana Medical
- Lead Manager in the DKK 1.5 billion Capital Increase by Zealand Pharma
- Capital Markets Advisor & Placement Agent in the merger between European Biotech Acquisition Corp. and Oculis SA and the connected USD 91 million PIPE
- Lead Manager in the USD 250 million US Public Offering by CureVac
- Sole Financial Adviser to GenSight Biologics in securing a €12.0 million credit facility from Heights Capital Management
- Joint Global Coordinator and Joint Bookrunner in the SEK 416 million Capital Increase by Hansa Biopharma
- Sole Financial Adviser in SynAct Pharma’s acquisition of TXP Pharma and Joint Global Coordinator & Joint Bookrunner in SynAct Pharma’s SEK 80m PIPE
- Joint Bookrunner in the SEK 200 million Accelerated Bookbuild Offering by Vicore Pharma
- Joint Global Bookrunner in the SEK 148 million Fully Guaranteed Rights Issue by Biovica
- Sole Financial Adviser to GenSight Biologics in securing a €35.0 million credit facility from the European Investment Bank (EIB)
- Joint Global Coordinator & Joint Bookrunner in the SEK 170 million Accelerated Bookbuild offering of Xbrane Biopharma
- Co-Lead Manager in the DKK 786 million Capital Increase by Zealand Pharma
- Financial Advisor in the sale of Sanquin Reagents by Sanquin Health Solutions to Gilde Healthcare
- Financial Advisor in the up to SEK 250 million (convertible) debt financing by Mendus
- Joint Global Coordinator in the SEK 299 million Directed Share Issue by BioInvent
- Sole Global Coordinator in the SEK 200 million financing consisting of a SEK 150m PIPE and a SEK 50m Fully Guaranteed Rights Issue by Abliva
- Joint Global Coordinator & Joint Bookrunner in the SEK 150 million Fully Guaranteed Rights Issue by SynAct Pharma
- Financial adviser in the spin-out and capital increase of InnoSIGN